Kailera Therapeutics KLRA Phase 1 Data: Tri-Agonist Shows Up To 16% Weight Loss
Kailera Therapeutics reported Phase 1 data for its tri-agonist, showing up to 16.0% mean weight loss at 12 mg over 12 weeks, with safety consistent with GLP-1s.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.